ReviewNature biomedical engineering2024
Cell-drug conjugates.
Review in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Organization from cell to tissue derived delivery systems for immunotherapy.Materials today. Bio · 2026Article
- Dopamine polymerization-mediated surface functionalization of living cells for advanced therapeutic applications.Nature protocols · 2026Review
- Mesenchymal Stromal Cell-Based Cell-Drug Conjugates for the Treatment of Acute Liver Failure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable-bacteria-macrophage backpacks for enhanced solid tumor therapy via mechanobiological interplay.Cell reports. Medicine · 2026Article
- T cell-nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy.Science advances · 2026Article
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Loading is not delivering: Intracellular drug retention and migration capacity govern macrophage-based drug delivery.Science advances · 2026Article
- Cell-Mediated Drug Delivery: From Carriers to Therapeutics.Pharmaceutics · 2026Article
- "Artificial platelet injection system": a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation.Bioactive materials · 2026Article
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Targeted Therapies for Each Subtype of Breast Cancer.MedComm · 2026Review
- Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Redox-modulating macrophage biohybrid nanoplatform for targeted RIPK1-PANoptosome suppression in ischemic stroke.Redox biology · 2026Article
- Biomimetic lung-targeting vehicle coupled with cryo-shocked leukocyte and inflammation-anchored liposome for drug delivery and anti-inflammation in treatment of acute pneumonia.Regenerative biomaterials · 2026Article
- Neutrophil-based delivery platforms: from natural mechanisms to engineered therapeutics.Theranostics · 2026Review
- Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications.Pharmaceutics · 2025Review
- Integrating Microorganism-Based Therapy and Emerging Biotechnology in the Treatment of Intracranial Central Nervous System Diseases.Pharmaceutics · 2025Review
- Multiplexed polypeptide-based hybrid bacterial clusters by tailoring the conjugation for synergistic treatment of infected wounds.Materials today. Bio · 2025Article
- DON-Loaded Nanodrug-T Cell Conjugates With PD-L1 Blockade for Solid Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
By combining living cells with therapeutics, cell-drug conjugates can potentiate the functions of both components, particularly for applications in drug delivery and therapy. The conjugates can be designed to persist in the bloodstream, undergo chemotaxis, evade surveillance by the immune system, proliferate, or maintain or transform their cellular phenotypes. In this Review, we discuss strategies for the design of cell-drug conjugates with specific functions, the techniques for their preparation, and their applications in the treatment of cancers, autoimmune diseases and other pathologies. We also discuss the translational challenges and opportunities of this class of drug-delivery systems and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.